The  ||| S:0 E:4 ||| DT
involvement  ||| S:4 E:16 ||| NN
of  ||| S:16 E:19 ||| IN
RCAS1  ||| S:19 E:25 ||| CD
in  ||| S:25 E:28 ||| IN
creating  ||| S:28 E:37 ||| VBG
a  ||| S:37 E:39 ||| DT
suppressive  ||| S:39 E:51 ||| JJ
tumor  ||| S:51 E:57 ||| NN
microenvironment  ||| S:57 E:74 ||| NN
in  ||| S:74 E:77 ||| IN
patients  ||| S:77 E:86 ||| NNS
with  ||| S:86 E:91 ||| IN
pharyngeal  ||| S:91 E:102 ||| FW
squamous  ||| S:102 E:111 ||| FW
cell  ||| S:111 E:116 ||| FW
carcinoma  ||| S:116 E:126 ||| FW
Tumor  ||| S:126 E:132 ||| FW
microenvironment  ||| S:132 E:149 ||| FW
makes  ||| S:149 E:155 ||| VBZ
up  ||| S:155 E:158 ||| RP
the  ||| S:158 E:162 ||| DT
stroma  ||| S:162 E:169 ||| NN
of  ||| S:169 E:172 ||| IN
the  ||| S:172 E:176 ||| DT
neoplasm  ||| S:176 E:185 ||| NN
and  ||| S:185 E:189 ||| CC
is  ||| S:189 E:192 ||| VBZ
the  ||| S:192 E:196 ||| DT
tissue  ||| S:196 E:203 ||| NN
that  ||| S:203 E:208 ||| WDT
determines  ||| S:208 E:219 ||| VBZ
the  ||| S:219 E:223 ||| DT
growth  ||| S:223 E:230 ||| NN
and  ||| S:230 E:234 ||| CC
progression  ||| S:234 E:246 ||| NN
of  ||| S:246 E:249 ||| IN
the  ||| S:249 E:253 ||| DT
tumor  ||| S:253 E:259 ||| NN
and  ||| S:259 E:263 ||| CC
its  ||| S:263 E:267 ||| PRP$
ability  ||| S:267 E:275 ||| NN
to  ||| S:275 E:278 ||| TO
create  ||| S:278 E:285 ||| VB
metastases ||| S:285 E:295 ||| NNS
.  ||| S:295 E:297 ||| .
THE  ||| S:297 E:301 ||| DT
AIM  ||| S:301 E:305 ||| NNP
OF  ||| S:305 E:308 ||| IN
THE  ||| S:308 E:312 ||| DT
PRESENT  ||| S:312 E:320 ||| NNP
STUDY ||| S:320 E:325 ||| NNP
:  ||| S:325 E:327 ||| :
has  ||| S:327 E:331 ||| VBZ
been  ||| S:331 E:336 ||| VBN
to  ||| S:336 E:339 ||| TO
evaluate  ||| S:339 E:348 ||| VB
the  ||| S:348 E:352 ||| DT
potential  ||| S:352 E:362 ||| JJ
role  ||| S:362 E:367 ||| NN
of  ||| S:367 E:370 ||| IN
RCAS1  ||| S:370 E:376 ||| CD
protein  ||| S:376 E:384 ||| NN
in  ||| S:384 E:387 ||| IN
creating  ||| S:387 E:396 ||| VBG
the  ||| S:396 E:400 ||| DT
suppressive  ||| S:400 E:412 ||| FW
tumor  ||| S:412 E:418 ||| FW
microenvironment  ||| S:418 E:435 ||| FW
in  ||| S:435 E:438 ||| FW
pharyngeal  ||| S:438 E:449 ||| FW
squamous  ||| S:449 E:458 ||| FW
cell  ||| S:458 E:463 ||| FW
carcinomas ||| S:463 E:473 ||| FW
.  ||| S:473 E:475 ||| .
The  ||| S:475 E:479 ||| DT
immunoreactivity  ||| S:479 E:496 ||| NN
of  ||| S:496 E:499 ||| IN
RCAS1 ||| S:499 E:504 ||| NNP
,  ||| S:504 E:506 ||| ,
CD3 ||| S:506 E:509 ||| NNP
,  ||| S:509 E:511 ||| ,
CD25 ||| S:511 E:515 ||| NNP
,  ||| S:515 E:517 ||| ,
CD68 ||| S:517 E:521 ||| NNP
,  ||| S:521 E:523 ||| ,
CD69  ||| S:523 E:528 ||| NNP
and  ||| S:528 E:532 ||| CC
Foxp3  ||| S:532 E:538 ||| NNP
was  ||| S:538 E:542 ||| VBD
assessed  ||| S:542 E:551 ||| VBN
in  ||| S:551 E:554 ||| IN
the  ||| S:554 E:558 ||| DT
tissue  ||| S:558 E:565 ||| NN
samples  ||| S:565 E:573 ||| NNS
of  ||| S:573 E:576 ||| IN
the  ||| S:576 E:580 ||| DT
tumor ||| S:580 E:585 ||| NN
,  ||| S:585 E:587 ||| ,
in  ||| S:587 E:590 ||| IN
tumor  ||| S:590 E:596 ||| NN
microenvironment  ||| S:596 E:613 ||| NNS
and  ||| S:613 E:617 ||| CC
in  ||| S:617 E:620 ||| IN
the  ||| S:620 E:624 ||| DT
reference  ||| S:624 E:634 ||| NN
samples  ||| S:634 E:642 ||| NNS
of  ||| S:642 E:645 ||| IN
palatine  ||| S:645 E:654 ||| JJ
tonsils  ||| S:654 E:662 ||| NN
in  ||| S:662 E:665 ||| IN
chronic  ||| S:665 E:673 ||| JJ
inflammation ||| S:673 E:685 ||| NN
.  ||| S:685 E:687 ||| .
A  ||| S:687 E:689 ||| DT
statistically  ||| S:689 E:703 ||| NN
significantly  ||| S:703 E:717 ||| RB
higher  ||| S:717 E:724 ||| JJR
RCAS1  ||| S:724 E:730 ||| NN
antigen  ||| S:730 E:738 ||| NN
immunoreactivity  ||| S:738 E:755 ||| NNS
was  ||| S:755 E:759 ||| VBD
identified  ||| S:759 E:770 ||| VBN
in  ||| S:770 E:773 ||| IN
pharyngeal  ||| S:773 E:784 ||| JJ
cancer  ||| S:784 E:791 ||| NN
samples  ||| S:791 E:799 ||| NNS
than  ||| S:799 E:804 ||| IN
in  ||| S:804 E:807 ||| IN
the  ||| S:807 E:811 ||| DT
stromal  ||| S:811 E:819 ||| JJ
samples ||| S:819 E:826 ||| NNS
,  ||| S:826 E:828 ||| ,
the  ||| S:828 E:832 ||| DT
presence  ||| S:832 E:841 ||| NN
of  ||| S:841 E:844 ||| IN
RCAS1  ||| S:844 E:850 ||| CD
positive  ||| S:850 E:859 ||| JJ
macrophages  ||| S:859 E:871 ||| NNS
infiltrating  ||| S:871 E:884 ||| VBG
the  ||| S:884 E:888 ||| DT
tumor  ||| S:888 E:894 ||| NN
and  ||| S:894 E:898 ||| CC
its  ||| S:898 E:902 ||| PRP$
stroma  ||| S:902 E:909 ||| NN
was  ||| S:909 E:913 ||| VBD
also  ||| S:913 E:918 ||| RB
noticed ||| S:918 E:925 ||| VBN
.  ||| S:925 E:927 ||| .
The  ||| S:927 E:931 ||| DT
statistically  ||| S:931 E:945 ||| NN
significantly  ||| S:945 E:959 ||| RB
higher  ||| S:959 E:966 ||| JJR
RCAS1  ||| S:966 E:972 ||| NN
antigen  ||| S:972 E:980 ||| NN
immunoreactivity  ||| S:980 E:997 ||| NN
level  ||| S:997 E:1003 ||| NN
was  ||| S:1003 E:1007 ||| VBD
identified  ||| S:1007 E:1018 ||| VBN
in  ||| S:1018 E:1021 ||| IN
the  ||| S:1021 E:1025 ||| DT
pharyngeal  ||| S:1025 E:1036 ||| JJ
cancer  ||| S:1036 E:1043 ||| NN
samples  ||| S:1043 E:1051 ||| NNS
in  ||| S:1051 E:1054 ||| IN
patients  ||| S:1054 E:1063 ||| NNS
with  ||| S:1063 E:1068 ||| IN
the  ||| S:1068 E:1072 ||| DT
presence  ||| S:1072 E:1081 ||| NN
of  ||| S:1081 E:1084 ||| IN
lymph  ||| S:1084 E:1090 ||| JJ
node  ||| S:1090 E:1095 ||| JJ
metastases  ||| S:1095 E:1106 ||| NN
in  ||| S:1106 E:1109 ||| IN
comparison  ||| S:1109 E:1120 ||| NN
to  ||| S:1120 E:1123 ||| TO
patients  ||| S:1123 E:1132 ||| NNS
without  ||| S:1132 E:1140 ||| IN
metastases ||| S:1140 E:1150 ||| NN
.  ||| S:1150 E:1152 ||| .
The  ||| S:1152 E:1156 ||| DT
infiltration  ||| S:1156 E:1169 ||| NN
of  ||| S:1169 E:1172 ||| IN
CD68  ||| S:1172 E:1177 ||| CD
positive  ||| S:1177 E:1186 ||| JJ
cells  ||| S:1186 E:1192 ||| NNS
( ||| S:1192 E:1193 ||| -LRB-
macrophages ||| S:1193 E:1204 ||| LS
)  ||| S:1204 E:1206 ||| -RRB-
was  ||| S:1206 E:1210 ||| VBD
significantly  ||| S:1210 E:1224 ||| RB
higher  ||| S:1224 E:1231 ||| JJR
in  ||| S:1231 E:1234 ||| IN
the  ||| S:1234 E:1238 ||| DT
stromal  ||| S:1238 E:1246 ||| JJ
tissue  ||| S:1246 E:1253 ||| NN
samples  ||| S:1253 E:1261 ||| NNS
than  ||| S:1261 E:1266 ||| IN
in  ||| S:1266 E:1269 ||| IN
cancer  ||| S:1269 E:1276 ||| NN
samples  ||| S:1276 E:1284 ||| NNS
and  ||| S:1284 E:1288 ||| CC
it  ||| S:1288 E:1291 ||| PRP
was  ||| S:1291 E:1295 ||| VBD
in  ||| S:1295 E:1298 ||| IN
both ||| S:1298 E:1302 ||| DT
,  ||| S:1302 E:1304 ||| ,
the  ||| S:1304 E:1308 ||| DT
tumor  ||| S:1308 E:1314 ||| NN
and  ||| S:1314 E:1318 ||| CC
the  ||| S:1318 E:1322 ||| DT
stroma ||| S:1322 E:1328 ||| NN
,  ||| S:1328 E:1330 ||| ,
significantly  ||| S:1330 E:1344 ||| RB
higher  ||| S:1344 E:1351 ||| JJR
in  ||| S:1351 E:1354 ||| IN
patients  ||| S:1354 E:1363 ||| NNS
with  ||| S:1363 E:1368 ||| IN
the  ||| S:1368 E:1372 ||| DT
presence  ||| S:1372 E:1381 ||| NN
of  ||| S:1381 E:1384 ||| IN
lymph  ||| S:1384 E:1390 ||| JJ
node  ||| S:1390 E:1395 ||| JJ
metastases  ||| S:1395 E:1406 ||| NN
than  ||| S:1406 E:1411 ||| IN
in  ||| S:1411 E:1414 ||| IN
patients  ||| S:1414 E:1423 ||| NNS
without  ||| S:1423 E:1431 ||| IN
metastases ||| S:1431 E:1441 ||| NN
.  ||| S:1441 E:1443 ||| .
Additionally  ||| S:1443 E:1456 ||| RB
the  ||| S:1456 E:1460 ||| DT
presence  ||| S:1460 E:1469 ||| NN
of  ||| S:1469 E:1472 ||| IN
CD3  ||| S:1472 E:1476 ||| CD
positive  ||| S:1476 E:1485 ||| JJ
TILs  ||| S:1485 E:1490 ||| NN
was  ||| S:1490 E:1494 ||| VBD
noticed  ||| S:1494 E:1502 ||| VBN
in  ||| S:1502 E:1505 ||| IN
the  ||| S:1505 E:1509 ||| DT
tissue  ||| S:1509 E:1516 ||| NN
of  ||| S:1516 E:1519 ||| IN
the  ||| S:1519 E:1523 ||| DT
tumor  ||| S:1523 E:1529 ||| NN
and  ||| S:1529 E:1533 ||| CC
in  ||| S:1533 E:1536 ||| IN
its  ||| S:1536 E:1540 ||| PRP$
stroma ||| S:1540 E:1546 ||| NN
,  ||| S:1546 E:1548 ||| ,
the  ||| S:1548 E:1552 ||| DT
cells  ||| S:1552 E:1558 ||| NNS
were  ||| S:1558 E:1563 ||| VBD
activated ||| S:1563 E:1572 ||| VBN
,  ||| S:1572 E:1574 ||| ,
typified  ||| S:1574 E:1583 ||| VBD
by  ||| S:1583 E:1586 ||| IN
CD69  ||| S:1586 E:1591 ||| CD
immunoreactivity  ||| S:1591 E:1608 ||| NNS
which  ||| S:1608 E:1614 ||| WDT
was  ||| S:1614 E:1618 ||| VBD
higher  ||| S:1618 E:1625 ||| JJR
than  ||| S:1625 E:1630 ||| IN
in  ||| S:1630 E:1633 ||| IN
the  ||| S:1633 E:1637 ||| DT
reference  ||| S:1637 E:1647 ||| NN
samples ||| S:1647 E:1654 ||| NNS
,  ||| S:1654 E:1656 ||| ,
and  ||| S:1656 E:1660 ||| CC
impaired  ||| S:1660 E:1669 ||| JJ
cytotoxicity  ||| S:1669 E:1682 ||| NN
with  ||| S:1682 E:1687 ||| IN
low  ||| S:1687 E:1691 ||| JJ
CD25  ||| S:1691 E:1696 ||| FW
antigen  ||| S:1696 E:1704 ||| FW
immunoreactivity ||| S:1704 E:1720 ||| FW
.  ||| S:1720 E:1722 ||| .
This  ||| S:1722 E:1727 ||| DT
observation  ||| S:1727 E:1739 ||| NN
confirmed  ||| S:1739 E:1749 ||| VBD
the  ||| S:1749 E:1753 ||| DT
presence  ||| S:1753 E:1762 ||| NN
of  ||| S:1762 E:1765 ||| IN
selective  ||| S:1765 E:1775 ||| JJ
immune  ||| S:1775 E:1782 ||| JJ
suppression  ||| S:1782 E:1794 ||| NN
within  ||| S:1794 E:1801 ||| IN
the  ||| S:1801 E:1805 ||| DT
tumor  ||| S:1805 E:1811 ||| NN
and  ||| S:1811 E:1815 ||| CC
the  ||| S:1815 E:1819 ||| DT
stroma ||| S:1819 E:1825 ||| NN
.  ||| S:1825 E:1827 ||| .
RCAS1 ||| S:1827 E:1832 ||| NNP
,  ||| S:1832 E:1834 ||| ,
an  ||| S:1834 E:1837 ||| DT
active  ||| S:1837 E:1844 ||| JJ
factor  ||| S:1844 E:1851 ||| NN
secreted  ||| S:1851 E:1860 ||| NN
by  ||| S:1860 E:1863 ||| IN
the  ||| S:1863 E:1867 ||| DT
tumor  ||| S:1867 E:1873 ||| NN
and  ||| S:1873 E:1877 ||| CC
present  ||| S:1877 E:1885 ||| JJ
in  ||| S:1885 E:1888 ||| IN
its  ||| S:1888 E:1892 ||| PRP$
stroma  ||| S:1892 E:1899 ||| NN
may  ||| S:1899 E:1903 ||| MD
play  ||| S:1903 E:1908 ||| VB
an  ||| S:1908 E:1911 ||| DT
important  ||| S:1911 E:1921 ||| JJ
role  ||| S:1921 E:1926 ||| NN
in  ||| S:1926 E:1929 ||| IN
the  ||| S:1929 E:1933 ||| DT
phenomenon  ||| S:1933 E:1944 ||| NN
of  ||| S:1944 E:1947 ||| IN
tumor  ||| S:1947 E:1953 ||| NN
escape  ||| S:1953 E:1960 ||| NN
from  ||| S:1960 E:1965 ||| IN
host  ||| S:1965 E:1970 ||| NN
immunological  ||| S:1970 E:1984 ||| NN
surveillance  ||| S:1984 E:1997 ||| NN
and  ||| S:1997 E:2001 ||| CC
in  ||| S:2001 E:2004 ||| IN
creating  ||| S:2004 E:2013 ||| VBG
the  ||| S:2013 E:2017 ||| DT
immune  ||| S:2017 E:2024 ||| JJ
tolerance  ||| S:2024 E:2034 ||| NN
for  ||| S:2034 E:2038 ||| IN
the  ||| S:2038 E:2042 ||| DT
tumor  ||| S:2042 E:2048 ||| NN
cells ||| S:2048 E:2053 ||| NNS
,  ||| S:2053 E:2055 ||| ,
as  ||| S:2055 E:2058 ||| RB
well  ||| S:2058 E:2063 ||| RB
as  ||| S:2063 E:2066 ||| RB
in  ||| S:2066 E:2069 ||| IN
the  ||| S:2069 E:2073 ||| DT
tumor  ||| S:2073 E:2079 ||| NN
microenvironment  ||| S:2079 E:2096 ||| NN
remodeling  ||| S:2096 E:2107 ||| NN
with  ||| S:2107 E:2112 ||| IN
creating  ||| S:2112 E:2121 ||| VBG
its  ||| S:2121 E:2125 ||| PRP$
suppressive  ||| S:2125 E:2137 ||| JJ
profile  ||| S:2137 E:2145 ||| NN
enabling  ||| S:2145 E:2154 ||| VBG
the  ||| S:2154 E:2158 ||| DT
further  ||| S:2158 E:2166 ||| JJ
tumor  ||| S:2166 E:2172 ||| NN
growth  ||| S:2172 E:2179 ||| NN
and  ||| S:2179 E:2183 ||| CC
metastases ||| S:2183 E:2193 ||| NN
.  ||| S:2193 E:2195 ||| .
